/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

A

Aoife Carr

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

41

Papers

354

Citations

13

h-index

14

i10-index

Aoife Carr is an academic researcher. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Cancer Genomics and Diagnostics. The author has an h-index of 13, co-authored 35 publications.

Research Topics

HER2/EGFR in Cancer Research Advanced Breast Cancer Therapies Cancer Genomics and Diagnostics Cancer Treatment and Pharmacology Lung Cancer Treatments and Mutations

Papers by this author

works

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

2014 · Breast Cancer Research and Treatment · 49 citations

https://doi.org/10.1007/s10549-014-3239-5

Naomi Elster Mattia Cremona Clare Morgan Sinéad Toomey

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

2017 · Breast Cancer Research · 34 citations

https://doi.org/10.1186/s13058-017-0883-9

Sinéad Toomey Alex J. Eustace Joanna Fay Katherine M. Sheehan

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)

2018 · PLoS ONE · 22 citations

https://doi.org/10.1371/journal.pone.0200996

Damien Côté Alex J. Eustace Sinéad Toomey Mattia Cremona

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

2016 · Oncotarget · 20 citations

https://doi.org/10.18632/oncotarget.12782

Sinéad Toomey Stephen F. Madden Simon J. Furney Yue Fan

Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

2023 · International Journal of Molecular Sciences · 10 citations

https://doi.org/10.3390/ijms241310545

Cathy E. Richards Yasir Y. Elamin Aoife Carr Kathy Gately

Additional file 2 of Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

2021 · Figshare · 0 citations

https://doi.org/10.6084/m9.figshare.14526521

M. Janusz Mezynski Angela M. Farrelly Mattia Cremona Aoife Carr

Research topics

topics

HER2/EGFR in Cancer Research

Advanced Breast Cancer Therapies

Cancer Genomics and Diagnostics

Cancer Treatment and Pharmacology

Lung Cancer Treatments and Mutations

Chat about Author

Papers

Chat

Click to start Chat